Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-17T20:02:32.026Z Has data issue: false hasContentIssue false

14 - Screening for familial ovarian cancer

Published online by Cambridge University Press:  24 August 2009

Barnaby Rufford
Affiliation:
St Bartholomew's and The Royal London School of Medicine and Dentistry, London, UK
Usha Menon
Affiliation:
St Bartholomew's and The Royal London School of Medicine and Dentistry, London, UK
Ian Jacobs
Affiliation:
St Bartholomew's and The Royal London School of Medicine and Dentistry, London, UK
Patrick J. Morrison
Affiliation:
Belfast City Hospital, Belfast
Shirley V. Hodgson
Affiliation:
Guy's Hospital, London
Neva E. Haites
Affiliation:
University of Aberdeen
Get access

Summary

Despite advances in surgery and chemotherapy, the overall prognosis for ovarian cancer remains poor. It has improved little over the last 30 years. The best way of improving outcome may be to detect the condition at an early stage through screening the population at risk. The high incidence of disease in those with a strong family history of ovarian cancer makes them particularly amenable to this strategy.

Why should we screen?

There are estimated to be approximately 50 000 women in the UK who have a significant family history of ovarian cancer with two or more affected close relatives. These women have an approximately ten-fold increased risk compared with the general population. This translates to an average lifetime risk of developing ovarian cancer of 15%.

The prognosis for ovarian cancer is generally poor, with an overall 5-year survival of about 30%. Seventy per cent of women are diagnosed with stage III or IV disease, with 5-year survivals of 15–20% and less than 5% respectively (Teneriello and Park, 1995). The lack of symptoms of early ovarian cancer results in women frequently presenting with advanced disease. This is due to the location of the ovaries within the peritoneal cavity, which results in minimal local irritation or interference with vital structures until ovarian enlargement is considerable, or metastasis occurs. Initial symptoms may be so vague that multiple consultations with a GP may occur before a gynaecological referral is initiated.

Type
Chapter
Information
Familial Breast and Ovarian Cancer
Genetics, Screening and Management
, pp. 220 - 234
Publisher: Cambridge University Press
Print publication year: 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×